However, it is important to bear in mind that CD37 is not a universal target for B cell malignancies, and it cannot be targeted in every B cell malignancy, e.g., not in ALL and multiple myelomas, since the antigen is not present at the beginning of differentiation and becomes reduced in plasma cells [8]. Here, CD37 is linked to plasma cell myeloma.